Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abexinostat in Relapsed/Refractory DLBCL (Phase II, Single-Arm)
CTR20191605Phase 2Active
- Sponsor
- Beijing Pharmaceutic Consulting
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abexinostat in diffuse large B-cell lymphoma (DLBCL), sponsored by Beijing Pharmaceutic Consulting. Started Aug 2019; status: active.
02
Drugs
abexinostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20191605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191605.